Generic Name and Formulations:
Arformoterol tartrate 15mcg/2mL; inhalation soln.
Indications for BROVANA:
Long-term maintenance treatment of bronchoconstriction due to COPD. Limitations of use: not for treating asthma or acute deteriorations of COPD.
By nebulizer: 15mcg by inhalation twice daily (AM & PM); max 30mcg/day. Use standard jet (eg, PARI LC Plus) nebulizer with air compressor (eg, PARI DURA-NEB 3000). Reevaluate periodically.
LABA use in asthma patients without use of long-term control medication.
LABAs increase risk of asthma-related death. Do not exceed recommended dose. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Hepatic impairment (monitor). Thyrotoxicosis. Hypokalemia. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Monitor potassium and blood glucose levels. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Pregnancy (Cat.C). Labor & delivery. Nursing mothers.
Long-acting beta-2 agonist (LABA).
See Contraindications. Avoid other sympathomimetics (except short-acting bronchodilators). Caution with MAOIs, tricyclics, or drugs known to prolong the QTc interval; may increase risk of arrhythmias. Antagonized by β-blockers. K+-depleting diuretics, theophylline, aminophylline, steroids may potentiate hypokalemia.
Pain, chest pain, back pain, diarrhea, sinusitis, leg cramps, dyspnea, rash, flu syndrome, peripheral edema, lung disorder; cardiovascular effects (eg, increased pulse rate or BP, ECG changes); rarely: paradoxical bronchospasm, hypersensitivity reactions.
Vials (2mL)—30, 60
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency